Dr. Zhang on second-line treatment and beyond in refractory metastatic renal cell carcinoma
March 10th 2023“One of the key challenges in the refractory renal cell population is identifying mechanisms of resistance to immune checkpoint inhibitors, and really delving in and figuring out how to target those mechanisms of resistance,” says Zhang.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Dr. Shore on overall safety profile of darolutamide in prostate cancer patients
March 3rd 2023“What we saw in phase 3 studies and what we've seen in earlier studies—early phase 1/2 studies—is really a paucity of cognitive impairment and a paucity of depression with darolutamide that we've seen across the class of androgen receptor signaling inhibitors,” says Neal Shore, MD.
Dr. Maha Hussain highlights results of secondary analysis of ARASENS trial
February 28th 2023The secondary analysis Hussain presented at the GU Symposium showed that the risk of death was reduced by 32% across all volume and subgroups in men with mHSPC treated with the darolutamide-based triplet regimen.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Dr. Efstathiou on significance of genomic testing in prostate cancer
February 24th 2023“We need to pursue further education in the field and reach out to every community practice and make them understand that we do now have the guidelines in place, the reimbursement in place, and cost is going down for actually adding system-wide germline and somatic testing for these patients,” says Eleni Efstathiou, MD, PhD.
Salvage nivolumab/ipilimumab effective in RCC patients unresponsive to upfront nivolumab
February 21st 2023Patients with renal cell carcinoma who had progressive disease or stable disease after frontline nivolumab had a substantial treatment-free survival period following salvage immunotherapy with nivolumab plus ipilimumab.
Dr. Rezazadeh discusses dosing and safety of darolutamide, ADT, and docetaxel in patients with mHSPC
February 21st 2023"Looking at the effect of the darolutamide on docetaxel, we didn't see much of a difference in dose reduction, dose modification, or dose hold for docetaxel, telling you that darolutamide didn't really affect the dosing of docetaxel," says Arash Rezazadah Kalebasty, MD.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
February 20th 2023Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
Dr. Cookson highlights results of PROpel trial for mCRPC
February 20th 2023"This trial did not require a biomarker for entry in, so patients were treated with combination therapy or standard care, which would have been the abiraterone alone, to see if there was a benefit," says Michael S. Cookson, MD, MMHC.
Nivolumab/cabozantinib shows improvements in long-term survival for RCC
February 19th 2023Median progression-free survival in the intent-to-treat population by blinded independent central review was 16.6 months (95% CI, 12.8-19.8) with nivolumab plus cabozantinib vs 8.4 months (95% CI, 7.0-9.7) with sunitinib (HR, 0.58; 95% CI, 0.48-0.71).